Chronic Disseminated Intravascular Coagulation(Chronic DIC) DIC
Conditions
Interventions
Sponsors
Nakayama Takayuki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with a diagnosis of DIC on the basis of criteria established by the new criteria for DIC research from the Japanase Society of Hemostasis and Thrombosis (2017 version) . 2) Patients aged 15 years and over at the time of consent acquisition . 3) Informed consents are obtained form patients or legal representatives. 4) Patients with clinical symptons such as thrombocytopenia and/or fibrinogenopenia induced by DIC.
Exclusion criteria
Exclusion criteria: 1 Patients with a history or present illness of severe allergy to a drug 2 Patients with severe renal disorder (< CLcr 30mL/min) 3 Patients whom the study drug might induce to bleed 4 Patients believed to die early even if they recovered from DIC, making it difficult to ensure a sufficient period of administration of the study drug and to obtain data on the efficacy and safety 5 Pregnant women, nursing mothers or possibly pregnant women 6 Patients whom the investigator considers to be unsuitable for participation in the study 7 Patients with severe hepatic disorder (< CLcr 30mL/min) 8 Patients treated with direct oral anticoagulants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of apixaban for patients with chronic disseminated intravascular coagulation. DIC score after administration of apixaban (in a week, three weeks, six weeks, 10 weeks, 18 weeks and 6 months) | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety of apixaban for patients with chronic disseminated intravascular coagulation. Adverse event 1. Symptoms of bleeding or organ 2. Outcome of the patients 3. The results of coagulations parameters (Fibrinogen, AT, TAT, Soluble fibrin, Plasminogen, alfa-2PI, PIC, FDP, D-dimer): before start of medication, after one week of medication, after three weeks of medication, after six weeks of medication, after ten weeks of medication, after eighteen weeks of medication, and after six months of medication 4. Adherence of the medicine | — |
Contacts
Public ContactShohei Mizuno
Aichi Medical University Hospital
Outcome results
None listed